Skip to main content
    X

    Xeris Pharmaceuticals Inc (XERS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.07
    +0.30 (+3.07%)

    Market Cap: $1.78B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    45%(15/33)
    Avg Surprise
    -4.68%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.03
    Range$-0.15 - $0.04
    3 analysts
    EPS RevisionsNo revisions (7d)
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.04-162.8%
    60d ago$0.04-172.8%
    30d ago$-0.02-33.5%
    7d ago$-0.02-33.5%
    Current$-0.03
    Revenue Consensus
    $102M
    Range$100M - $103M
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.01
    Range$-0.08 - $0.10
    3 analysts
    Revenue Consensus
    $116M
    Range$114M - $119M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.01---
    Sep 26EST
    		-$-0.03---
    Jun 26
    Reported Aug 6
    		$-0.01$0.02-150.00%Miss+0.0%
    Mar 26
    Reported May 7
    		$0.01$-0.01+200.00%Beat+116.7%
    Dec 25
    Reported Mar 2
    		$0.06$0.02+261.45%Beat+300.0%
    Sep 25
    Reported Nov 6
    		$0.00N/A-65.00%Miss+105.8%
    Jun 25
    Reported Aug 7
    		$-0.01N/A+66.67%Beat+90.0%
    Mar 25
    Reported May 8
    		$-0.06$-0.04-50.00%Miss+57.1%
    Dec 24
    Reported Mar 6
    		$-0.03$-0.02-50.00%Miss+70.0%
    Sep 24
    Reported Nov 8
    		$-0.06$-0.08+25.00%Beat+33.3%
    Jun 24
    Reported Aug 8
    		$-0.10$-0.09-11.11%Miss+28.6%
    Mar 24
    Reported May 9
    		$-0.14$-0.11-27.27%Miss-16.7%
    Dec 23
    Reported Mar 6
    		$-0.10$-0.10+0.00%Beat+0.0%
    Sep 23
    Reported Nov 9
    		$-0.09$-0.10+10.00%Beat+43.8%
    Jun 23
    Reported Aug 8
    		$-0.14$-0.11-27.27%Miss+26.3%
    Mar 23
    Reported May 9
    		$-0.12$-0.15+20.00%Beat+52.0%
    Dec 22
    Reported Mar 8
    		$-0.10$-0.16+37.50%Beat+76.2%
    Sep 22
    Reported Nov 9
    		$-0.16$-0.15-6.67%Miss+59.0%
    Jun 22
    Reported Aug 10
    		$-0.19$-0.22+13.64%Beat+53.7%
    Mar 22
    Reported May 11
    		$-0.25$-0.24-4.17%Miss+16.7%
    Dec 21
    Reported Mar 10
    		$-0.42$-0.24-75.00%Miss-2.4%
    Sep 21
    Reported Nov 10
    		$-0.39$-0.37-5.41%Miss-11.4%
    Jun 21
    Reported Aug 5
    		$-0.41$-0.30-36.67%Miss+34.9%
    Mar 21
    Reported May 13
    		$-0.30$-0.34+11.76%Beat+66.3%
    Dec 20
    Reported Mar 9
    		$-0.41$-0.38-7.89%Miss+66.7%
    Sep 20
    Reported Nov 9
    		$-0.35$-0.52+32.69%Beat+71.3%
    Jun 20
    Reported Aug 10
    		$-0.63$-0.73+13.70%Beat+50.8%
    Mar 20
    Reported May 7
    		$-0.89$-0.89+0.00%Beat+16.8%
    Dec 19
    Reported Mar 11
    		$-1.23$-1.13-8.85%Miss-25.5%
    Sep 19
    Reported Nov 7
    		$-1.22$-1.23+0.81%Beat-71.8%
    Jun 19
    Reported Aug 6
    		$-1.28$-0.94-36.17%Miss+58.3%
    Mar 19
    Reported May 9
    		$-1.07$-0.76-40.79%Miss+77.2%
    Dec 18
    Reported Mar 6
    		$-0.98$-0.93-5.38%Miss+24.0%
    Sep 18
    Reported Nov 7
    		$-0.71$-0.78+8.97%Beat+84.0%
    Jun 18
    Reported Aug 13
    		$-3.07$-0.88-248.86%Miss+17.4%
    Mar 18
    Reported Jun 21
    		$-4.69$0.00N/AMiss-1939.1%
    Dec 17
    Reported Mar 30
    		$-1.29$0.00N/AMiss+43.8%
    Sep 17
    Reported Dec 31
    		$-4.43$0.00N/AMiss-
    Jun 17
    Reported Sep 30
    		$-3.72$0.00N/AMiss-
    Mar 17
    Reported Jun 29
    		$-0.23$0.00N/AMiss-
    Dec 16
    Reported Mar 30
    		$-2.29$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio158.58EV/EBITDA35.37x
    Price/FCF31.26xFCF Yield3.20%
    Profitability
    Profit Margin-5.12%Operating Margin5.62%
    ROE-617.00%ROIC11.90%
    Financial Health
    Debt/Equity-25.95xInterest Coverage0.62x
    Current Ratio1.45xQuick Ratio1.02x
    Trading Statistics
    Beta0.84Avg Volume3.36M
    52-Week High$11.3352-Week Low$5.25

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$10.06
    SMA 20$9.58
    SMA 50$8.81
    SMA 200$7.33
    EMA 10$9.97
    EMA 20$9.62
    EMA 50$8.97
    EMA 200$7.70

    MACD

    Line: 0.45Signal: 0.44Hist: 0.01

    ADX

    ADX: 41.8+DI: 32.1-DI: 15.3

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down4.0
    PSAR$10.95

    Bollinger Bands

    Upper Band$10.94
    Lower Band$8.23
    %B Position2830%(Upper)
    Band Width0.68

    RSI (14-Day)

    Neutral
    59.9

    Momentum Oscillators

    Stoch %K47.4
    Stoch %D56.4
    Williams %R-54.1
    ROC (10d)8.9%
    Momentum0.82
    CCI (20d)48.0
    MFI (14d)71.8

    Volatility Measures

    ATR (14d)$0.50(5.0%)
    StdDev (20d)0.68
    Hist Vol65.0%(High)

    Volume Flow

    VWAP$10.01
    OBV80.0M
    AD Line5.2M
    CMF (20d)-0.057

    Volume Metrics

    Avg Vol (20d)3.5M
    Vol Ratio0.6x
    VWMA (20d)$9.66

    Pivot Points

    R3$10.86
    R2$10.62
    R1$10.20
    Pivot Point$9.96
    S1$9.54
    S2$9.30
    S3$8.88

    Advanced Oscillators

    TSI26.86
    Ultimate Osc46.4
    KST198.44

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$92.10M$83.13M$85.81M$74.38M$71.54M$60.12M$60.10M$54.27M$48.06M$40.64M$44.39M$48.32M
    Cost of Revenue$12.51M$10.57M$10.95M$11.00M$11.90M$8.73M$9.48M$13.59M$7.79M$5.97M$15.13M$8.20M
    Gross Profit$79.59M$72.55M$74.86M$63.38M$59.64M$51.39M$50.62M$40.67M$40.27M$34.67M$29.27M$40.12M
    Operating Expenses$74.42M$64.64M$58.09M$56.65M$55.16M$54.48M$48.94M$53.57M$48.46M$48.91M$39.11M$45.03M
    R&D$10.67M$8.78M$7.87M$7.48M$8.05M$7.75M$6.09M$5.89M$5.76M$7.82M$6.38M$5.03M
    SG&A$61.03M$53.14M$47.50M$46.46M$44.39M$44.02M$40.14M$44.97M$39.99M$38.38M$37.57M$37.29M
    Operating Income$5.17M$7.92M$16.77M$6.73M$4.48M$-3,090,000$1.68M$-12,893,000$-8,187,000$-14,245,000$-9,841,000$-4,913,000
    Interest Income$1.46M$1.20M$1.46M$1.16M$948,000$1.18M$910,000$1.20M$1.29M$1.92M$1.11M$1.12M
    Interest Expense$37.73M$6.88M$7.15M$7.27M$7.36M$7.30M$7.70M$7.79M$7.96M$9.72M$7.02M$9.68M
    Income Before Tax$-31,101,000$2.23M$11.08M$621,000$-1,928,000$-9,220,000$-5,113,000$-19,062,000$-14,256,000$-18,673,000$-13,626,000$-12,527,000
    Income Tax Expense$0$0$0$0$0$0$0$-3,324,000$749,000$307,000$-236,000$-338,000
    Net Income$-31,101,000$2.23M$11.08M$621,000$-1,928,000$-9,220,000$-5,113,000$-15,738,000$-15,005,000$-18,980,000$-13,390,000$-12,189,000
    EBITDA$9.29M$12.02M$20.84M$10.76M$8.47M$897,000$5.56M$-8,738,000$-3,920,000$-7,271,000$-4,075,000$-341,000
    EBIT$5.17M$7.92M$16.77M$6.73M$4.48M$-3,090,000$1.68M$-12,473,000$-7,583,000$-10,874,000$-7,715,000$-3,964,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about XERS

    News

    Xeris Biopharma presents data on endocrine therapies at fall meetings

    Xeris Biopharma Holdings, Inc. announced presentations of clinical and scientific data from its commercial portfolio and development pipeline at three scientific meetings. The presentations cover Gvoke for severe...

    Investing.com•10/15/26•Bullish

    Xeris files KEVEYIS patent suits and Xeris Biopharma Holdings stock trades at EUR 8.60

    Xeris Biopharma Holdings has filed two patent infringement lawsuits regarding generic versions of its drug KEVEYIS, seeking injunctions and damages. This legal action follows a strong second quarter in 2026...

    ad-hoc-news.de•10/15/26•Somewhat-Bullish

    Form 4 Xeris Biopharma Holdings, Inc: Steven Pieper (Officer) For: 1 October

    This article reports that Steven Pieper, an Officer at Xeris Biopharma Holdings, Inc., filed a Form 4 on October 1st. Form 4 filings are used to declare transactions in company stock by corporate insiders. The article...

    Investing.com Nigeria•10/13/26•Neutral

    Xeris Biopharma COO McCulloch sells $141,120 in shares

    Kevin McCulloch, COO of Xeris Biopharma Holdings, sold 15,000 shares of the company's common stock for $141,120 on October 1, 2026, pursuant to a pre-arranged trading plan. Despite the sale...

    Investing.com•10/13/26•Neutral

    Xeris Biopharma CLO Beth Hecht sells $156,792 in XERS shares

    Beth Hecht, CLO of Xeris Biopharma, sold 16,666 shares of XERS stock for approximately $156,792 on October 1, 2026, under a Rule 10b5-1 trading plan. Following the sale...

    Investing.com•10/13/26•Somewhat-Bearish

    XERS Valuation and Fair Value

    P/E
    158.6x
    Forward P/E
    36.9x
    EV/EBITDA
    35.4x
    P/FCF
    31.3x
    P/B
    -178.8x
    See GNG's fair value

    XERS Profitability: Margins, ROIC and FCF

    Gross margin
    86.6%
    Operating margin
    5.6%
    Net margin
    -5.1%
    ROIC
    11.9%
    ROE
    -617.0%
    FCF margin
    16.6%
    FCF yield
    3.2%

    XERS Competitors

    CompanyTicker
    Galapagos NV ADRGLPG
    Sarepta Therapeutics IncSRPT
    Mineralys Therapeutics, Inc. Common StockMLYS
    Palvella Therapeutics, IncPVLA
    Surgery Partners IncSGRY
    Vir Biotechnology IncVIR
    UroGen Pharma LtdURGN
    Xencor IncXNCR

    Sector: Healthcare

    XERS Analyst Ratings

    Consensus
    Buy
    Analysts
    7
    Strong Buy
    1
    Buy
    5
    Hold
    1
    Sell
    0
    Strong Sell
    0

    XERS Bull Case vs Bear Case

    Bull case

    • XERS converts 16.6% of revenue into free cash flow.
    • XERS grew quarterly revenue 28.7% year over year.
    • 85.7% of XERS's analyst ratings are Buy or Strong Buy.

    Bear case

    • XERS trades at 158.6x trailing earnings.
    • XERS has a -5.1% net profit margin.

    XERS Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    29.8%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.03
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 1 down

    Frequently Asked Questions About XERS

    Does XERS pay dividends?

    Xeris Pharmaceuticals Inc (XERS) does not currently pay a regular dividend.

    What is XERS's P/E ratio?

    Xeris Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 158.58.

    What is XERS's market cap?

    Xeris Pharmaceuticals Inc (XERS) has a market capitalization of $1.78B with a current stock price of $10.07.

    Related stocks

    Sector: Healthcare

    All stocks starting with X

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In